Compare Citius Pharmaceuticals Inc (CTXR) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs SYSCO Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while SYSCO Corporation trades at $78.14 (market cap $38.47B). The key difference: SYSCO Corporation is far larger — about 2824.5× Citius Pharmaceuticals Inc's market cap, and SYSCO Corporation pays a 2.81% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and SYSCO Corporation for 77 Days on average.
| CTXR | SYY | |
|---|---|---|
Market Cap | $13.62M | $38.47B |
Volume | 132,438 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $91.16 |
52-Week Low | $0.48 | $69.30 |
Typical Hold Time | 17 Days | 77 Days |
Enterprise Value | $3.79M | $51.65B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Sysco (SYY) trades at $78.20, up 1.84% with neutral technical signals. The company shows steady revenue growth to $81.37B in 2025, though net margins remain thin at 2.08%. Recent corporate actions include a $1.5B senior notes offering and a $500M AI efficiency program targeting cost savings. Analyst consensus is bullish with 60% buy ratings and an $85.75 price target, representing 9.6% upside potential from current levels.
Sysco presents a balanced investment case with strong institutional support and dividend stability, but faces margin pressure and high debt levels. The AI efficiency initiative and consistent revenue growth provide catalysts, while competitive pressures and economic sensitivity pose risks. Current valuation appears reasonable with P/E of 21.37 and P/S of 0.44.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
